Hereditary Angioedema Intellia Therapeutics
![hereditary Angioedema Intellia Therapeutics hereditary Angioedema Intellia Therapeutics](https://www.intelliatx.com/wp-content/uploads/infographic_hae@2x.png)
Hereditary Angioedema Intellia Therapeutics Hereditary angioedema (hae) is a rare but serious, genetic condition associated with frequent episodes or attacks of painful swelling in various parts of the body. learn more from intellia therapeutics. Hereditary angioedema is a rare genetic disease that leads to severe and unpredictable swelling attacks. kellie kolb, palak sharma, and zachary dymek (all of intellia therapeutics) for.
![hereditary Angioedema Intellia Therapeutics hereditary Angioedema Intellia Therapeutics](https://www.intelliatx.com/wp-content/uploads/masthead_disease-areas_hae@2x.jpg)
Hereditary Angioedema Intellia Therapeutics Intellia’s multi national phase 1 2 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ntla 2002 in adults with type i or type ii hereditary angioedema (hae). this includes the measurement of plasma kallikrein protein levels and clinical activity as determined by hae attack rate measures. Intellia’s global phase 1 2 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ntla 2002 in adults with type i or type ii hereditary angioedema (hae). this includes the measurement of plasma kallikrein protein levels and activity, as well as hae attack rate. Intellia’s ongoing phase 1 2 study is evaluating the safety and activity of ntla 2002 in adults with type i or type ii hereditary angioedema (hae). the phase 1 2 is an international, open label study designed to identify a dose level of ntla 2002 for further evaluation in a phase 3 study. Intellia therapeutics announces publication of positive interim phase 1 data for ntla 2002 in patients with hereditary angioedema in the new england journal of medicine. cambridge, mass., jan. 31.
Comments are closed.